Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide

Introduction: Plasma androgen receptor (AR) copy number (CN) status identifies castration-resistant prostate cancer (CRPC) patients with worse outcome on abiraterone/enzalutamide. However, the impact of AR CN changes on clinical outcome in CRPC is unknown. Materials and Methods: Plasma samples from...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Autores principales: Gurioli, Giorgia, Conteduca, Vincenza, Lolli, Cristian, Schepisi, Giuseppe, Gargiulo, Stefania, Altavilla, Amelia, Casadei, Chiara, Scarpi, Emanuela, De Giorgi, Ugo
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7542981/
https://ncbi.nlm.nih.gov/pubmed/33072600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.567809
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares